We advised the underwriters on the IPO and NYSE listing

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 18,750,000 shares of common stock of Enfusion, Inc. at $17.00 per share, including the full exercise of the underwriters’ option to purchase an additional 2,812,500 shares for total gross proceeds of approximately $318.75 million. The offering consisted of 15,322,660 shares issued and sold by Enfusion, and 3,427,340 shares sold by the selling shareholders. The common stock is listed on the New York Stock Exchange under the symbol “ENFN.”

Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one cloud-native system. Through its software, analytics and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion partners with 600+ investment managers from nine global offices spanning four continents.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Shane Tintle and associates Clare Conroy and Roshni Bhalla. The tax team included partner Ethan R. Goldman and associates Liang Zhang and Benjamin Helfgott. The intellectual property and technology transactions team included partner Matthew J. Bacal and associate Joshua Cameron Shirley. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk deal team are based in the New York office.